# Verification report

**Run:** `a581f22a-d145-4903-99bf-9052dd6f22e9`  
**Generated:** 2026-05-12T16:33:29+00:00  
**Total cost:** $0.6308

## Summary

| Verdict | Count |
|---|---|
| Supported | 19 |
| Partially supported | 2 |
| Unsupported | 0 |
| Not addressed | 8 |
| Unverifiable | 7 |
| **Total** | **36** |

**Citation resolution:** 33/36 found (92%)
**Fulltext access:** verified=20, no_passage=0, unavailable=16
**Numeric checks:** 9 run, 0 inconsistencies

> **Warning:** 4 citation(s) resolved with low confidence — verify manually.

## Claims

### 1. [UNVERIFIABLE] Gerstein (2021)

> Efpeglenatide (AMPLITUDE-O) demonstrated a hazard ratio of 0.73 (95% CI, 0.58–0.92; P=0.007) for MACE versus placebo in adults with type 2 diabetes.

- **Source:** [10.1056/nejmoa2108269](https://doi.org/10.1056/nejmoa2108269) — *Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes*
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only
- **Unverifiable reason:** `numeric_claim_abstract_only`

**Why:** Pipeline could not verify this claim with the evidence it was able to retrieve (abstract_only). The verifier LLM emitted 'supported' based on the abstract_only alone, but that depth of evidence is insufficient for a confident verdict on this claim (numeric_claim_abstract_only). Original LLM explanation: The abstract explicitly reports that efpeglenatide versus placebo in the AMPLITUDE-O trial yielded a hazard ratio of 0.73 (95% CI, 0.58 to 0.92; P = 0.007 for superiority) for MACE in adults with type 2 diabetes, exactly matching the claim'...

### 2. [SUPPORTED] Marso (2016) — confidence 0.99

> Liraglutide (LEADER) demonstrated a hazard ratio of 0.87 (95% CI, 0.78–0.97; P=0.01 for superiority) for MACE versus placebo.

- **Source:** [10.1056/nejmoa1603827](https://doi.org/10.1056/nejmoa1603827) — *Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage
- **Numeric check:** consistent (or_ci_consistency) — OR/CI internally consistent: 0.78 <= 0.87 <= 0.97, CI ratio within plausibility bounds.

**Passages:**

> The primary composite outcome occurred in fewer patients in the liraglutide group (608 of 4668 patients [13.0%]) than in the placebo group (694 of 4672 [14.9%]) (hazard ratio, 0.87; 95% confidence interval [CI], 0.78 to 0.97; P<0.001 for noninferiority; P = 0.01 for superiority)

**Why:** The passage explicitly reports the hazard ratio of 0.87 (95% CI, 0.78 to 0.97; P=0.01 for superiority) for the primary composite outcome (MACE) in the LEADER trial, directly matching the claim.

### 3. [SUPPORTED] Husain (2020) — confidence 0.99

> Subcutaneous semaglutide (SUSTAIN 6) demonstrated superiority for MACE reduction with HR 0.74 (95% CI, 0.58–0.95).

- **Source:** [10.1111/dom.13955](https://doi.org/10.1111/dom.13955) — *Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage
- **Numeric check:** consistent (or_ci_consistency) — OR/CI internally consistent: 0.58 <= 0.74 <= 0.95, CI ratio within plausibility bounds.

**Passages:**

> There were fewer MACE with semaglutide versus placebo in both trials: the hazard ratios (HRs) for SUSTAIN 6 and PIONEER 6 were 0.74 (95% confidence interval [CI] 0.58, 0.95) and 0.79 (0.57, 1.11), respectively.
> In SUSTAIN 6, the results were significant for noninferiority and superiority, although the latter was not prespecified.
> SUSTAIN 6 HR: 0.74 (95% CI 0.58, 0.95) P<0.001 for noninferiority P=0.02 for superiority†

**Why:** The passage explicitly states the HR for MACE in SUSTAIN 6 was 0.74 (95% CI 0.58, 0.95) with P<0.001 for noninferiority and P=0.02 for superiority, directly confirming the claim about subcutaneous semaglutide (SUSTAIN 6) demonstrating superiority for MACE reduction with the specified HR and confidence interval.

### 4. [SUPPORTED] — (2025) — confidence 0.99

> Oral semaglutide (SOUL trial) showed significant MACE reduction with HR 0.86 (95% CI, 0.77–0.96; P=0.006).

- **Source:** [10.21522/tijar.2014.12.02.art012](https://doi.org/10.21522/tijar.2014.12.02.art012) — *Unveiling Cardiovascular Benefits of Oral Semaglutide in High-Risk Type 2 Diabetes: Findings from the SOUL Trial*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage
- **Numeric check:** consistent (or_ci_consistency) — OR/CI internally consistent: 0.77 <= 0.86 <= 0.96, CI ratio within plausibility bounds.

**Passages:**

> A major adverse cardiovascular event (MACE) occurred in 12.0% of semaglutide-treated patients and 13.8% of those receiving placebo (HR 0.86; 95% CI, 0.77–0.96; p=0.006).
> The primary endpoint, a composite of MACE, occurred in 579 patients (11.9%) in the oral semaglutide group and 668 patients (13.9%) in the placebo group. This corresponded to a hazard ratio (HR) of 0.86 (95% CI, 0.77–0.96; p=0.006).

**Why:** The passage explicitly reports that MACE occurred with HR 0.86 (95% CI, 0.77–0.96; p=0.006) in the SOUL trial, directly matching all values in the claim including direction, magnitude, confidence interval, and p-value.

### 5. [SUPPORTED] Holman (2017) — confidence 0.99

> EXSCEL (exenatide) met noninferiority but failed to demonstrate superiority for MACE (HR 0.91; 95% CI, 0.83–1.00; P=0.06).

- **Source:** [10.1056/nejmoa1612917](https://doi.org/10.1056/nejmoa1612917) — *Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage
- **Numeric check:** consistent (or_ci_consistency) — OR/CI internally consistent: 0.83 <= 0.91 <= 1.0, CI ratio within plausibility bounds.

**Passages:**

> A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P = 0.06 for superiority).

**Why:** The passage explicitly reports the hazard ratio of 0.91 (95% CI, 0.83 to 1.00) for MACE in the EXSCEL trial, with noninferiority demonstrated (P<0.001) but superiority not achieved (P=0.06), which exactly matches the claim.

### 6. [UNVERIFIABLE] Bethel (2020)

> Sensitivity analyses in EXSCEL adjusting for unbalanced drop-in of cardioprotective medications in the placebo arm yielded a significant MACE result (HR 0.85; P=0.008).

- **Source:** [10.1161/circulationaha.119.043353](https://doi.org/10.1161/circulationaha.119.043353) — *Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes*
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only
- **Unverifiable reason:** `numeric_claim_abstract_only`

**Why:** Pipeline could not verify this claim with the evidence it was able to retrieve (abstract_only). The verifier LLM emitted 'supported' based on the abstract_only alone, but that depth of evidence is insufficient for a confident verdict on this claim (numeric_claim_abstract_only). Original LLM explanation: The abstract explicitly states that 'IPTW decreased the MACE HR from 0.91 (P=0.061) to 0.85 (P=0.008),' which directly supports the claim that sensitivity analyses adjusting for unbalanced drop-in of cardioprotective medications yielded a s...

### 7. [NOT ADDRESSED] Gerstein (2023) — confidence 0.99

> A dose-response relationship was demonstrated with efpeglenatide across all primary and secondary outcomes (all P for trend ≤0.018).

- **Source:** [10.1161/cir.0000000000001186](https://doi.org/10.1161/cir.0000000000001186) — *A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association* **(LOW CONFIDENCE)**
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only

**Why:** The source abstract is a broad scientific statement about cardiovascular-kidney-metabolic (CKM) syndrome covering mechanisms, prevention, and management. It does not mention efpeglenatide, dose-response relationships, or any specific clinical trial outcomes related to the claim.

### 8. [SUPPORTED] Leiter (2020) — confidence 0.97

> No heterogeneity in MACE reduction was observed across blood pressure categories for liraglutide and semaglutide (P-interaction = 0.06 and 0.40).

- **Source:** [10.1111/dom.14079](https://doi.org/10.1111/dom.14079) — *The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage

**Passages:**

> There was no statistical heterogeneity across the BP categories for the effects of liraglutide (P = .06 for MACE; P = .14 for nephropathy) or semaglutide (P = .40 for MACE; P = .27 for nephropathy) versus placebo.
> Although there appeared to be a trend with liraglutide versus placebo towards a lower relative risk reduction in those with normal BP (compared with those with stage 1 or 2 hypertension), this was not statistically significant (P-interaction = .06).

**Why:** The passage explicitly states that there was no statistical heterogeneity across BP categories for MACE reduction with liraglutide (P-interaction = .06) and semaglutide (P-interaction = .40), which directly matches the claim's assertion.

### 9. [SUPPORTED] Rossing (2023) — confidence 0.98

> Semaglutide showed consistent MACE reduction across all eGFR and UACR subgroups (P-interaction >0.05) in pooled SUSTAIN 6 and PIONEER 6 analysis.

- **Source:** [10.1186/s12933-023-01949-7](https://doi.org/10.1186/s12933-023-01949-7) — *Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage

**Passages:**

> Semaglutide consistently reduced MACE risk versus placebo across all eGFR and UACR subgroups (interaction p value [pINT] > 0.05).
> The treatment effects for semaglutide versus placebo for first MACE were similar across eGFR subgroups (Fig. 2); HRs [95% CI] for participants with eGFR ≥ 60, ≥45–<60 and < 45 mL/min/1.73 m2 were 0.72 [0.56;0.93], 0.74 [0.46;1.19] and 0.72 [0.42;1.24], respectively (pINT = 1.00; Fig. 2).
> The pINT value indicated that there was no treatment heterogeneity across UACR subgroups (pINT = 0.48).

**Why:** The passages explicitly state that semaglutide consistently reduced MACE risk versus placebo across all eGFR and UACR subgroups with interaction p-values greater than 0.05, directly supporting the claim.

### 10. [NOT ADDRESSED] Gilbert (2018) — confidence 0.70

> Liraglutide showed a 34% MACE reduction in patients aged ≥75 years versus a lesser reduction in those aged 60–74 years (P-interaction=0.054).

- **Source:** [10.7326/m18-1569](https://doi.org/10.7326/m18-1569) — *Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial*
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only

**Why:** The abstract title and authorship information are provided, but no abstract text containing specific numerical results (such as a 34% MACE reduction in patients aged ≥75 years or a P-interaction value of 0.054) is included. Without the actual abstract content, it is impossible to confirm or contradict the specific claim.

### 11. [SUPPORTED] Verma (2023) — confidence 0.90

> Semaglutide reduces the risk of MACE consistently across baseline triglyceride levels in patients with type 2 diabetes.

- **Source:** [10.1111/dom.15081](https://doi.org/10.1111/dom.15081) — *Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the <scp>SUSTAIN</scp> 6 and <scp>PIONEER</scp> 6 trials*
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only

**Why:** The title of the source explicitly states that 'Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes,' which directly matches the claim's core assertion. The source is described as post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials, providing the evidentiary basis for this conclusion.

### 12. [PARTIALLY SUPPORTED] Neves (2024) — confidence 0.65

> In EXSCEL, MACE HR was 0.96 (95% CI, 0.70–1.31) for LVEF <40% versus 0.84 (95% CI, 0.71–0.98) for LVEF ≥40% (P-interaction=0.47).

- **Source:** [10.1002/ejhf.3478](https://doi.org/10.1002/ejhf.3478) — *Cardiovascular Outcomes with Exenatide in Type 2 Diabetes According to Ejection Fraction: The EXSCEL Trial*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage
- **Numeric check:** consistent (or_ci_consistency) — OR/CI internally consistent: 0.7 <= 0.96 <= 1.31, CI ratio within plausibility bounds.

**Passages:**

> There were no significant interactions (p-interaction >0.10) of LVEF with treatment arm on MACE, cardiovascular death, hHF or cardiovascular death, hHF or MACE, ventricular tachyarrhythmia, or all-cause mortality (Table 2, Figure 1).

**Why:** The passage confirms that LVEF did not significantly modify the effect of EQW on MACE (p-interaction >0.10), which is consistent with the claim's P-interaction=0.47. However, the passage does not report the specific MACE HR values of 0.96 (95% CI, 0.70–1.31) for LVEF <40% or 0.84 (95% CI, 0.71–0.98) for LVEF ≥40% that the claim asserts.

### 13. [SUPPORTED] Marx (2025) — confidence 0.99

> In the SOUL trial, concomitant SGLT2 inhibitor use did not attenuate the MACE benefit of oral semaglutide (HR 0.89 with SGLT2i vs. 0.84 without; P-interaction=0.66).

- **Source:** [10.1161/circulationaha.125.074545](https://doi.org/10.1161/circulationaha.125.074545) — *Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage

**Passages:**

> In the subgroup of participants with SGLT2i at baseline, there were 143 of 1296 (11.0%) MACE events in the oral semaglutide group versus 158 of 1300 (12.2%) in the placebo group (HR, 0.89; 95% CI, 0.71–1.11).
> In the subgroup without SGLT2i at baseline, there were 436 of 3529 (12.4%) primary outcomes with semaglutide versus 510 of 3525 (14.5%) in participants with placebo (HR, 0.84; 95% CI, 0.74–0.95; P-interaction, 0.66; Figure 1A).

**Why:** The passage explicitly states the hazard ratios for MACE with and without SGLT2i use at baseline, and the P-interaction value, exactly matching the claim: HR 0.89 (95% CI, 0.71–1.11) with SGLT2i, HR 0.84 (95% CI, 0.74–0.95) without SGLT2i, and P-interaction of 0.66.

### 14. [SUPPORTED] Verma (2019) — confidence 0.99

> Liraglutide showed a 15.7% reduction in total (first + recurrent) MACE (HR 0.84; 95% CI, 0.76–0.93).

- **Source:** [10.1001/jamacardio.2019.3080](https://doi.org/10.1001/jamacardio.2019.3080) — *Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage
- **Numeric check:** consistent (or_ci_consistency) — OR/CI internally consistent: 0.76 <= 0.84 <= 0.93, CI ratio within plausibility bounds.

**Passages:**

> Liraglutide was associated with a 15.7% relative risk reduction in total MACE (hazard ratio [HR], 0.84; 95% CI, 0.76-0.93) and a 13.4% reduction in total expanded MACE (HR, 0.87; 95% CI, 0.81-0.93) compared with placebo.

**Why:** The passage explicitly states that liraglutide was associated with a 15.7% relative risk reduction in total MACE with HR 0.84 and 95% CI 0.76-0.93, which exactly matches the claim.

### 15. [PARTIALLY SUPPORTED] Verma (2018) — confidence 0.55

> In LEADER, liraglutide showed HR 0.82 (95% CI, 0.66–1.02) for MACE in patients with polyvascular disease and HR 0.82 (95% CI, 0.71–0.95) in those with single vascular disease.

- **Source:** [10.1161/circulationaha.118.033898](https://doi.org/10.1161/circulationaha.118.033898) — *Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease*
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only

**Why:** The abstract is from the LEADER trial paper specifically examining liraglutide's cardiovascular effects in patients with polyvascular disease, which is directly relevant to the claim. However, the abstract text provided does not explicitly state the HR values of 0.82 (95% CI, 0.66–1.02) for polyvascular disease or 0.82 (95% CI, 0.71–0.95) for single vascular disease — only the source title and author list are given without the actual abstract content containing these specific numerical results. Since the paper is clearly on-topic and likely contains these values, but the abstract text itself does not display the specific HR values to confirm them, only partial support can be assigned.

### 16. [SUPPORTED] Buse (2020) — confidence 0.97

> A mediation analysis from LEADER identified HbA1c as mediating up to 41–83% of liraglutide's cardiovascular benefit depending on analytical method, and urinary albumin-to-creatinine ratio mediating up to 29–33%.

- **Source:** [10.2337/dc19-2251](https://doi.org/10.2337/dc19-2251) — *Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage

**Passages:**

> Analyses using the Cox methods and Vansteelandt method indicated potential mediation by HbA1c (up to 41% and 83% mediation, respectively) and UACR (up to 29% and 33% mediation, respectively) on the effect of liraglutide on MACE.
> The estimated contribution of HbA1c as a mediator to the effect of liraglutide on MACE at 3 years was 82.0% (95% CI 11.7; 449.3), with the direct effect of liraglutide accounting for the remaining 18%of thetotal observed CV beneﬁt (Fig. 1 and Table 3).

**Why:** The passage explicitly states that analyses using the Cox methods indicated HbA1c mediation up to 41% and the Vansteelandt method indicated up to 83% (82.0% specifically), and UACR mediation of up to 29% and 33% respectively, directly matching the claim's stated ranges.

### 17. [UNVERIFIABLE] Mann (2017)

> In LEADER, the composite renal outcome was significantly reduced with liraglutide (HR 0.78; 95% CI, 0.67–0.92; P=0.003), driven primarily by reduced new-onset macroalbuminuria (HR 0.74; 95% CI, 0.60–0.91; P=0.004).

- **Source:** [10.1056/nejmoa1616011](https://doi.org/10.1056/nejmoa1616011) — *Liraglutide and Renal Outcomes in Type 2 Diabetes*
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only
- **Unverifiable reason:** `numeric_claim_abstract_only`

**Why:** Pipeline could not verify this claim with the evidence it was able to retrieve (abstract_only). The verifier LLM emitted 'supported' based on the abstract_only alone, but that depth of evidence is insufficient for a confident verdict on this claim (numeric_claim_abstract_only). Original LLM explanation: The abstract explicitly states that the renal outcome occurred in fewer participants in the liraglutide group (HR 0.78; 95% CI, 0.67 to 0.92; P=0.003), and that this was driven primarily by new onset of persistent macroalbuminuria (HR 0.74;...

### 18. [UNVERIFIABLE] Mentz (2018)

> In the prespecified subgroup with established cardiovascular disease in EXSCEL, exenatide achieved statistical significance for MACE reduction (P=0.047).

- **Source:** [10.1161/circulationaha.118.036811](https://doi.org/10.1161/circulationaha.118.036811) — *Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease*
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only
- **Unverifiable reason:** `numeric_claim_abstract_only`

**Why:** Pipeline could not verify this claim with the evidence it was able to retrieve (abstract_only). The verifier LLM emitted 'supported' based on the abstract_only alone, but that depth of evidence is insufficient for a confident verdict on this claim (numeric_claim_abstract_only). Original LLM explanation: The source is specifically about the effects of once-weekly exenatide in patients with preexisting cardiovascular disease from EXSCEL, which directly corresponds to the prespecified subgroup claim. The title and authorship (including Holman...

### 19. [SUPPORTED] Mann (2018) — confidence 0.99

> In LEADER, a post hoc analysis showed greater MACE reduction in patients with eGFR <60 (HR 0.69; 95% CI, 0.57–0.85) versus eGFR ≥60 (HR 0.94; 95% CI, 0.83–1.07; P-interaction=0.01).

- **Source:** [10.1161/circulationaha.118.036418](https://doi.org/10.1161/circulationaha.118.036418) — *Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage
- **Numeric check:** consistent (or_ci_consistency) — OR/CI internally consistent: 0.57 <= 0.69 <= 0.85, CI ratio within plausibility bounds.

**Passages:**

> In patients with eGFR <60 mL/min/1.73 m2, risk reduction for the primary composite cardiovascular outcome with liraglutide was greater (hazard ratio [HR], 0.69; 95% CI, 0.57–0.85) versus those with eGFR ≥60 mL/min/1.73 m2 (HR, 0.94; 95% CI, 0.83–1.07; interaction P=0.01).
> Liraglutide's treatment effects in patients with and without kidney disease were analyzed post hoc.

**Why:** The passage explicitly states the HR values and confidence intervals for both eGFR subgroups, and the interaction P-value of 0.01, directly matching the claim's specific assertions.

### 20. [SUPPORTED] Mann (2018) — confidence 0.98

> In LEADER, the interaction for MACE by eGFR was not significant when analyzed as a continuous variable (P-interaction=0.61) or across finer eGFR subgroups (P-interaction=0.13).

- **Source:** [10.1161/circulationaha.118.036418](https://doi.org/10.1161/circulationaha.118.036418) — *Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage

**Passages:**

> There was no consistent effect modification with liraglutide across finer eGFR subgroups (interaction P=0.13) and when analyzing eGFR as a continuous variable (interaction P=0.61).

**Why:** The passage explicitly states both P-interaction values that the claim asserts: when eGFR is analyzed as a continuous variable (interaction P=0.61) and across finer eGFR subgroups (interaction P=0.13), matching the claim exactly.

### 21. [SUPPORTED] Husain (2020) — confidence 0.97

> Combined SUSTAIN and PIONEER post hoc analysis showed reduced relative and absolute MACE risk across the entire cardiovascular risk continuum, with relative risk reduction tending to be largest at low CV risk score and absolute risk reduction greatest at intermediate-to-high CV risk.

- **Source:** [10.1186/s12933-020-01106-4](https://doi.org/10.1186/s12933-020-01106-4) — *Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage

**Passages:**

> There was a reduced relative and absolute risk of MACE for semaglutide vs comparators across the entire continuum of CV risk. While the relative risk reduction tended to be largest with low CV risk score, the largest absolute risk reduction was for intermediate to high CV risk score.
> There was a reduced relative risk of MACE with semaglutide vs comparators across the baseline CV risk continuum (Fig. 1), with a non-significant interaction p-value between CV risk score and treatment (p = 0.06), and a trend towards the largest relative CV benefits (i.e. lower hazard ratios) in those with the lowest CV risk score (i.e. lowest baseline CV risk).
> the absolute risk estimates for MACE with semaglutide vs comparators varied across the CV risk spectrum, with a trend for the largest absolute risk reduction in subjects at medium-to-high CV risk, as evidenced by the lowest NNT (111) being observed at a medium-to-high CV risk score of −0.483

**Why:** The passage explicitly states that semaglutide showed reduced relative and absolute MACE risk across the entire CV risk continuum, with relative risk reduction tending to be largest at low CV risk score and absolute risk reduction greatest at intermediate-to-high CV risk, directly matching the claim.

### 22. [SUPPORTED] Verma (2020) — confidence 0.98

> Patients with microvascular disease had higher baseline MACE risk (HR 1.15 in LEADER, 1.56 in SUSTAIN 6), but GLP-1 RA cardiovascular benefit was consistent regardless of microvascular disease status.

- **Source:** [10.1111/dom.14140](https://doi.org/10.1111/dom.14140) — *Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 clinical trials*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage

**Passages:**

> Patients with microvascular disease were shown to have an increased risk of major adverse cardiovascular events compared with patients without microvascular disease (hazard ratio [95% confidence interval] in LEADER: 1.15 [1.03; 1.29], P = .0136; SUSTAIN 6: 1.56 [1.14; 2.17], P = .0064).
> Liraglutide and semaglutide consistently reduced cardiovascular risk in patients with and without microvascular disease.
> Liraglutide and semaglutide reduced CV outcomes compared with placebo in patients with a history of microvascular disease; no heterogeneity in treatment effects was observed for subgroups by microvascular disease, with the exception of the neuropathy (yes/no) subgroups for MACE in SUSTAIN 6.

**Why:** The passage explicitly reports the HR values for baseline MACE risk in patients with microvascular disease (HR 1.15 [1.03; 1.29] in LEADER and HR 1.56 [1.14; 2.17] in SUSTAIN 6), and also states that liraglutide and semaglutide consistently reduced cardiovascular risk in patients with and without microvascular disease, with no heterogeneity in treatment effects observed.

### 23. [UNVERIFIABLE] Gerstein (2021)

> AMPLITUDE-O showed a significant reduction in the composite renal outcome with efpeglenatide (HR 0.68; 95% CI, 0.57–0.79; P<0.001).

- **Source:** [10.1056/nejmoa2108269](https://doi.org/10.1056/nejmoa2108269) — *Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes*
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only
- **Unverifiable reason:** `numeric_claim_abstract_only`

**Why:** Pipeline could not verify this claim with the evidence it was able to retrieve (abstract_only). The verifier LLM emitted 'supported' based on the abstract_only alone, but that depth of evidence is insufficient for a confident verdict on this claim (numeric_claim_abstract_only). Original LLM explanation: The abstract explicitly states: 'A composite renal outcome event (a decrease in kidney function or macroalbuminuria) occurred in 353 participants (13.0%) assigned to receive efpeglenatide and in 250 participants (18.4%) assigned to receive...

### 24. [NOT ADDRESSED] Gerstein (2021) — confidence 0.95

> In AMPLITUDE-O, efpeglenatide significantly reduced heart failure hospitalization (HR 0.61; 95% CI, 0.38–0.98).

- **Source:** [10.1056/nejmoa2108269](https://doi.org/10.1056/nejmoa2108269) — *Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes*
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only

**Why:** The abstract reports results for the primary composite MACE outcome (HR 0.73; 95% CI, 0.58–0.92) and a composite renal outcome (HR 0.68; 95% CI, 0.57–0.79), but does not mention heart failure hospitalization as a separate endpoint or report an HR of 0.61 (95% CI, 0.38–0.98) for any outcome. Heart failure hospitalization is not addressed in this abstract.

### 25. [SUPPORTED] Marso (2016) — confidence 0.99

> Liraglutide significantly reduced all-cause mortality by 15% (HR 0.85; 95% CI, 0.74–0.97).

- **Source:** [10.1056/nejmoa1603827](https://doi.org/10.1056/nejmoa1603827) — *Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage
- **Numeric check:** consistent (or_ci_consistency) — OR/CI internally consistent: 0.74 <= 0.85 <= 0.97, CI ratio within plausibility bounds.

**Passages:**

> The rate of death from any cause was lower in the liraglutide group (381 patients [8.2%]) than in the placebo group (447 [9.6%]) (hazard ratio, 0.85; 95% CI, 0.74 to 0.97; P =0.02).
> The rate of death from any cause was also lower in the liraglutide group (381 patients [8.2%]) than in the placebo group (447 [9.6%]) (hazard ratio, 0.85; 95% CI, 0.74 to 0.97; P = 0.02).

**Why:** The passage explicitly reports that the rate of death from any cause (all-cause mortality) was lower in the liraglutide group than in the placebo group with a hazard ratio of 0.85 (95% CI, 0.74 to 0.97; P=0.02), which corresponds to a 15% reduction. This exactly matches the claim's stated HR and CI.

### 26. [SUPPORTED] Marso (2016) — confidence 0.99

> In LEADER, cardiovascular death was significantly reduced with liraglutide (HR 0.78; 95% CI, 0.66–0.93; P=0.007).

- **Source:** [10.1056/nejmoa1603827](https://doi.org/10.1056/nejmoa1603827) — *Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage
- **Numeric check:** consistent (or_ci_consistency) — OR/CI internally consistent: 0.66 <= 0.78 <= 0.93, CI ratio within plausibility bounds.

**Passages:**

> Death from cardiovascular causes occurred in fewer patients in the liraglutide group (219 patients [4.7%]) than in the placebo group (278 [6.0%]) (hazard ratio, 0.78; 95% CI, 0.66 to 0.93; P = 0.007) (Fig. 1B).

**Why:** The passage explicitly reports that fewer patients died from cardiovascular causes in the liraglutide group than in the placebo group with a hazard ratio of 0.78, 95% CI 0.66 to 0.93, and P=0.007, which exactly matches the claim.

### 27. [SUPPORTED] Marso (2016) — confidence 0.98

> In LEADER, pancreatitis rates were numerically similar between liraglutide (18 events) and placebo (23 events), with no significant difference.

- **Source:** [10.1056/nejmoa1603827](https://doi.org/10.1056/nejmoa1603827) — *Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage

**Passages:**

> Acute pancreatitis occurred in 18 patients in the liraglutide group and in 23 in the placebo group.
> The incidence of pancreatitis was nonsignificantly lower in the liraglutide group than in the placebo group.

**Why:** The passage explicitly states that acute pancreatitis occurred in 18 patients in the liraglutide group and in 23 in the placebo group, and separately notes that 'The incidence of pancreatitis was nonsignificantly lower in the liraglutide group than in the placebo group,' directly supporting both the event counts and the lack of significant difference claimed.

### 28. [UNVERIFIABLE] Bethel (2020)

> Exenatide showed a nominally significant 14% reduction in all-cause mortality (HR 0.86; P=0.016) in the EXSCEL sensitivity analysis.

- **Source:** [10.1161/circulationaha.119.043353](https://doi.org/10.1161/circulationaha.119.043353) — *Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes*
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only
- **Unverifiable reason:** `numeric_claim_abstract_only`

**Why:** Pipeline could not verify this claim with the evidence it was able to retrieve (abstract_only). The verifier LLM emitted 'supported' based on the abstract_only alone, but that depth of evidence is insufficient for a confident verdict on this claim (numeric_claim_abstract_only). Original LLM explanation: The abstract explicitly states 'the ACM HR from 0.86 (P=0.016)' which directly corresponds to the claim of a 14% reduction in all-cause mortality (HR 0.86; P=0.016) being nominally significant in the EXSCEL sensitivity analysis context. The...

### 29. [NOT ADDRESSED] Gooding (2024) — confidence 0.95

> In EXSCEL, heart failure hospitalization HR was 0.94 (95% CI not specified).

- **Source:** [10.1016/j.diabres.2024.111685](https://doi.org/10.1016/j.diabres.2024.111685) — *Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? Insights from post-hoc analysis of EXSCEL*
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only

**Why:** The abstract focuses on whether sulfonylurea use modifies the cardiovascular effects of exenatide on MACE outcomes in EXSCEL, and does not report any hazard ratio for heart failure hospitalization. The claim's specific assertion about a heart failure hospitalization HR of 0.94 is not addressed anywhere in this abstract.

### 30. [SUPPORTED] — (2025) — confidence 0.98

> In the SOUL trial, gastrointestinal adverse events occurred in 16.6% of semaglutide-treated patients versus 8.2% with placebo.

- **Source:** [10.21522/tijar.2014.12.02.art012](https://doi.org/10.21522/tijar.2014.12.02.art012) — *Unveiling Cardiovascular Benefits of Oral Semaglutide in High-Risk Type 2 Diabetes: Findings from the SOUL Trial*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage

**Passages:**

> Gastrointestinal adverse events—primarily nausea, vomiting, and diarrhea—were more frequently reported with semaglutide (16.6%) than placebo (8.2%), especially during the initial dose escalation phase.

**Why:** The passage explicitly states that gastrointestinal adverse events were reported in 16.6% of semaglutide-treated patients and 8.2% of placebo patients in the SOUL trial, which exactly matches the claim.

### 31. [SUPPORTED] — (2025) — confidence 0.95

> In the SOUL trial, heart failure hospitalization was significantly reduced with oral semaglutide (HR 0.82; P=0.013).

- **Source:** [10.21522/tijar.2014.12.02.art012](https://doi.org/10.21522/tijar.2014.12.02.art012) — *Unveiling Cardiovascular Benefits of Oral Semaglutide in High-Risk Type 2 Diabetes: Findings from the SOUL Trial*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=quoted_passage

**Passages:**

> Furthermore, the reduction in hospitalization for heart failure (HR 0.82; p=0.013) challenges prior assumptions that GLP-1RAs offer minimal benefit in this domain and invites further exploration of the potential for oral semaglutide to modulate heart failure outcomes— particularly in preserved ejection fraction phenotypes [12].

**Why:** The passage explicitly states in the Discussion section that 'the reduction in hospitalization for heart failure (HR 0.82; p=0.013) challenges prior assumptions that GLP-1RAs offer minimal benefit in this domain,' which directly matches the claim's assertion of HR 0.82 and P=0.013 for heart failure hospitalization reduction with oral semaglutide in the SOUL trial.

### 32. [UNVERIFIABLE] Bethel (2020)

> In EXSCEL, 38.1% of placebo patients versus 28.8% of exenatide patients received additional open-label glucose-lowering therapies during follow-up, including SGLT2 inhibitors (10.3% vs. 8.1%) and open-label GLP-1 RAs (3.4% vs. 2.4%).

- **Source:** [10.1161/circulationaha.119.043353](https://doi.org/10.1161/circulationaha.119.043353) — *Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes*
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only
- **Unverifiable reason:** `numeric_claim_abstract_only`

**Why:** Pipeline could not verify this claim with the evidence it was able to retrieve (abstract_only). The verifier LLM emitted 'supported' based on the abstract_only alone, but that depth of evidence is insufficient for a confident verdict on this claim (numeric_claim_abstract_only). Original LLM explanation: The abstract explicitly states: 'open-label drop-in occurred in 33.4% of participants, more frequently with placebo than exenatide (38.1% versus 28.8%), with... SGLT-2i (10.3% versus 8.1%), GLP-1 RA (3.4% versus 2.4%),' which directly match...

### 33. [NOT ADDRESSED] Holman (2017) — confidence 0.85

> EXSCEL had an overall discontinuation rate of up to 45%.

- **Source:** [10.1056/nejmoa1612917](https://doi.org/10.1056/nejmoa1612917) — *Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes*
- **Evidence:** depth=fulltext, retrieval=passage_found, quality=passages_searched_no_quote

**Passages:**

> pmcN Engl J MedN Engl J Med319nihpaThe New England journal of medicine0028-47931533-4406pmc-is-collection-domainyespmc-collection-titleNIHPA Author ManuscriptsPMC9792409PMC9792409.197924099792409NIHMS18564612891023710.1056/NEJMoa1612917NIHMS1856461NIHPA18564611ArticleEffects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 DiabetesHolmanRury R.F.Med.Sci.Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, United KingdomBethelM. AngelynM.D.Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, United KingdomMentzRobert J.M.D.Duke Clinical Research Institute, Duke University School of Medicine, Durham, North CarolinaThompsonVivian P.M.P.H.Duke Clinical Research…

**Why:** The passages from the EXSCEL trial paper do not report an overall discontinuation rate of 'up to 45%.' The passages mention that the mean percentage of time participants received the trial regimen was approximately 75-76%, implying some discontinuation, but no specific discontinuation rate of 45% is stated or implied.

### 34. [NOT ADDRESSED] Gerstein (2023) — confidence 0.99

> The 6 mg efpeglenatide dose showed a significant 35% MACE reduction (HR 0.65; 95% CI, 0.50–0.86; P=0.003), while the 4 mg dose showed a nonsignificant 18% reduction (HR 0.82; 95% CI, 0.63–1.06; P=0.14).

- **Source:** [10.1161/cir.0000000000001186](https://doi.org/10.1161/cir.0000000000001186) — *A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association* **(LOW CONFIDENCE)**
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only

**Why:** The source abstract is a broad scientific statement about cardiovascular-kidney-metabolic (CKM) syndrome that does not mention efpeglenatide, specific MACE reduction percentages, hazard ratios, or any of the specific clinical trial results cited in the claim. The abstract does not contain the specific assertion about the 6 mg or 4 mg efpeglenatide doses and their associated MACE outcomes.

### 35. [NOT ADDRESSED] Gerstein (2023) — confidence 0.99

> In the AMPLITUDE-O dose-response analysis, the composite renal endpoint showed HR 0.63 for 6 mg (P<0.0001) and HR 0.73 for 4 mg (P=0.0009).

- **Source:** [10.1161/cir.0000000000001186](https://doi.org/10.1161/cir.0000000000001186) — *A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association* **(LOW CONFIDENCE)**
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only

**Why:** The abstract is a broad scientific statement about cardiovascular-kidney-metabolic (CKM) syndrome and does not contain any mention of the AMPLITUDE-O trial, dose-response analysis, or specific hazard ratios for composite renal endpoints at 6 mg or 4 mg doses.

### 36. [NOT ADDRESSED] Gerstein (2023) — confidence 0.98

> In AMPLITUDE-O dose-response analysis, the 6 mg efpeglenatide dose reduced cardiovascular death (HR 0.55; 95% CI, 0.35–0.88; P=0.012) and nonfatal MI (HR 0.64; 95% CI, 0.43–0.96; P=0.033), but not nonfatal stroke (HR 0.79; 95% CI, 0.47–1.34; P=0.38).

- **Source:** [10.1161/cir.0000000000001186](https://doi.org/10.1161/cir.0000000000001186) — *A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association* **(LOW CONFIDENCE)**
- **Evidence:** depth=abstract, retrieval=fulltext_unavailable, quality=abstract_only

**Why:** The abstract is a broad scientific statement about cardiovascular-kidney-metabolic syndrome and does not contain any specific data from the AMPLITUDE-O trial or any dose-response analysis of efpeglenatide, including the specific hazard ratios for cardiovascular death, nonfatal MI, or nonfatal stroke claimed.
